VHL and von Hippel-Lindau disease: The VHL-HIF-VEGF pathway is a compelling therapeutic target for both von Hippel-Lindau (VHL) syndrome and sporadic clear cell renal cell carcinoma (spRCC) patients, given the high prevalence of VHL mutations or alterations in these conditions.